Novartis has entered a multi-asset licensing and option agreement with Argo Biopharma, valued up to $5.2 billion, to access Argo’s siRNA cardiovascular drug candidates. The upfront payment totals $160 million, with milestone and royalty payments contingent on development progress. The partnership includes options for exclusive licensing of discovery-stage molecules targeting hypertriglyceridemia and mixed dyslipidemia, as well as rights to an ANGPTL3 inhibitor undergoing Phase II trials. This deal builds on a prior collaboration and aligns with Novartis’ strategy to incorporate RNA interference mechanisms to address global cardiovascular disease burdens.